The IBMD-OI Study - A Study to Assess the Effectiveness of Teriparatide (FORTEO) for Increasing Bone Mass and Improving Bone Structure in Adults Affected with Osteogenesis Imperfecta (OI)

NOTE: "IBMD-OI" refers to Improved Bone Mineral Density in Osteogenesis Imperfecta

The purpose of this study is to determine the effectiveness of teriparatide (FORTEO) for increasing bone mass and improving bone structure in adults affected with Osteogenesis Imperfecta (OI).

The working hypothesis is that individuals affected with OI who are treated with teriparatide will experience increased spine and hip bone mineral density and improvements in bone geometry (an increase in bone width and cortical thickness).